Syntekabio Appoints Joonhyuk Choi as Head of US Operations

Syntekabio (KOSDAQ: 226330), an AI-driven drug development company, has announced the appointment of Joonhyuk Choi, former CEO of Target Health, as Head of US Operations. The move is anticipated to enhance Syntekabio's strategic partnerships and revenue-generating initiatives in the US market.

Joonhyuk Choi brings over 25 years of experience in the pharmaceutical industry, with a background in electrical and computer engineering from Rutgers University. His career includes a strong track record in developing clinical trial software, managing clinical trials, navigating the US FDA’s drug and medical device approval processes, and leading business development.

Before joining Syntekabio, Choi served as CEO of Target Health, a US-based contract research organization (CRO). He was pivotal in clinical operations and business development, overseeing validated software solutions for clinical trials and data management.

Syntekabio expects Choi's expertise in AI-driven drug discovery, clinical trials, and drug approvals, combined with his knowledge of the US market, to significantly enhance the company’s strategic initiatives. Choi expressed his commitment to leveraging strategies tailored to the US pharma and biotech market to expand Syntekabio's global reach and impact.

Jongsun Jung, CEO of Syntekabio, noted that Choi's appointment strategically positions the company to collaborate with potential partners across the drug development spectrum, driving global expansion and enhancing competitiveness.

Syntekabio, founded in 2009, integrates biology with AI/ML to facilitate the rapid discovery of first-in-class and best-in-class compounds. The company operates its own supercomputer cloud and a global contract research organization network to validate computational results, offering clients comprehensive services to generate and optimize drug candidates.